Business Context and Reporting Period
Moleculin Biotech, Inc. (NASDAQ: MBRX) filed a Form 8-K Current Report on July 31, 2026, regarding a material definitive agreement. The company, a Delaware corporation, entered into a placement agency agreement with Roth Capital Partners, LLC, for a public offering of common stock and warrants. The transaction closed on August 3, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $9.3 million from the sale of securities, excluding warrant exercise proceeds.
- Securities Issued: 12,376,667 shares of Common Stock (or Pre-Funded Warrants) and Series I Common Stock Purchase Warrants to purchase up to 37,130,001 shares.
- Offering Price: $0.75 per share of Common Stock (or Pre-Funded Warrant) plus accompanying Common Warrant.
- Transaction Costs: A 6.5% cash fee to the Placement Agent and a 1.0% fee to financial advisor Maxim Group LLC. Reimbursement of out-of-pocket expenses capped at $100,000.
- Warrant Terms: Common Warrants have an exercise price of $0.75 and expire five years after the Initial Exercise Date. Pre-Funded Warrants have an exercise price of $0.001.
- Use of Proceeds: Intended to advance the clinical development of Annamycin and for working capital.
Material Changes and Agreements
The filing details the entry into a Securities Purchase Agreement and Placement Agreement. Key contractual obligations include:
- Lock-Up Periods: Directors and officers are restricted from selling shares for 60 days post-closing. The Company is restricted from issuing new equity for 45 days, with a 180-day restriction on Variable Rate Transactions (with an exception for at-the-market offerings starting day 46).
- Anti-Dilution Protection: Common Warrants include a price reset provision. If the Company issues stock below the $0.75 exercise price, the warrant price will reduce to the new issuance price, subject to a floor of $0.21.
- Ownership Caps: Holders are restricted from exercising warrants if it results in beneficial ownership exceeding 4.99% (or up to 9.99% at the holder's election).
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance the clinical development of Annamycin. The filing notes that the offering was made pursuant to a Registration Statement on Form S-1 declared effective on July 31, 2026. The text does not provide specific forward-looking financial guidance, revenue projections, or updated risk factors beyond the standard disclosures regarding the terms of the purchase and placement agreements.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 6.5% placement fee, 1.0% advisor fee, and other offering expenses.
- Confirm the exact mix of Common Stock versus Pre-Funded Warrants sold to determine immediate dilution versus potential future dilution.
- Review the specific clinical milestones for Annamycin to assess the sufficiency of the $9.3 million gross proceeds.
- Monitor the 45-day and 180-day lock-up periods for potential future equity issuances or at-the-market offerings.
- Check for any subsequent issuances of stock below the $0.75 threshold that would trigger the warrant price reset to the $0.21 floor.